Steve Chapman
CHIEF EXECUTIVE OFFICER
Steve Chapman is the chief executive officer of Natera and serves on the company’s board of directors.
Chapman is a leading authority on the commercialization of genetic testing. Under his leadership, Natera has launched 20 products that have transformed patient care, including two of the fastest growing genetic tests of all time. The company’s suite of products includes the Signatera™ oncology test for molecular residual disease, the Prospera™ transplant assessment test, the Renasight™ kidney gene panel which screens for genetic causes of chronic kidney disease, and the highly differentiated Panorama™ test serving patients in the non-invasive prenatal testing market.
Before his appointment as CEO in 2019, Chapman held a number of other leadership positions at Natera including chief operating officer. Earlier in his career, he worked at Genzyme Genetics. He began his career as a researcher in the department of human genetics at the University of California Los Angeles (UCLA), where he designed arrays identifying SNPs associated with multiple sclerosis.
Chapman serves on the board of directors for the American Clinical Laboratories Association (ACLA). In 2024, he was named one of the top healthcare technology CEOs by Healthcare Technology Report, as well as “BioTechnology Innovator of the Year” by BioTech Breakthrough.
He has been a guest on CNBC and other shows and podcasts to share more about Natera’s impact on patient care in the field of personalized genetic testing and diagnostics. He has also authored multiple scientific papers.
Chapman holds a bachelor’s degree in microbiology, immunology, and molecular genetics from UCLA, where he graduated with honors.
Follow him on LinkedIn.
